Retinoblastoma protein expression and MIB-1 correlate with survival of patients with malignant astrocytoma

Cancer

Volumn 80, Issue 2, 1997, Pages 242-249

  Nakamura, Mitsutoshi ^a   Konishi, Noboru ^a   Tsunoda, Shigeru ^b   Hiasa, Yoshio ^a   Tsuzuki, Toshihide ^a   Inui, Takuo ^a   Sakaki, Toshisuke ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b Osaka Prefecture University   (Japan)

Author keywords

Anaplastic astrocytoma; Apoptosis; MIB 1; p53; Retinoblastoma protein

Indexed keywords

MONOCLONAL ANTIBODY KI 67; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; ASTROCYTOMA; CANCER SURVIVAL; CELL PROLIFERATION; DIAGNOSIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETINOBLASTOMA; TREATMENT OUTCOME;

ADULT; AGED; APOPTOSIS; ASTROCYTOMA; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETINOBLASTOMA PROTEIN; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030978836     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970715)80:2<242::AID-CNCR12>3.0.CO;2-U     Document Type: Article

References (48)

1. Devaux BC, O'Fallon JR, Kelly PJ. Resection, biopsy, and survival in malignant glial neoplasms: a retrospective study of clinical parameters, therapy and outcome. J Neurosurg 1993;78:767-75.
2. Ganju V, Jenkins RB, OOFallon JR, Scheithauer BW, Ransom DT, Katzmann JA, et al. Prognostic factors in gliomas. Cancer 1994;74:920-7.
3. Henson JW, Schnitker BL, Correa KM, von Deimling A, Fassbender F, Xu H-J, et al. The retinoblastoma gene is involved in in malignant progression of astrocytomas. Ann Neurol 1994;36:714-21.
4. Nakamura M, Konishi N, Hiasa Y, Tsunoda S, Fukushima Y, Tsuzuki T, et al. Immunohistochemical detection of CDKN2, retinoblastoma and p53 gene products in primary astrocytic tumors, Int J Oncol 1996;8:889-93.
5. Wakimoto H, Aoyagi M, Nakamura T, Nagashima G, Yamamoto S, Tamaki M, et al. Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas. Cancer 1996;77:373-80.
6. Winger MJ, Macdonald DR, Cairncross JG. Supratentorial anaplastic gliomas in adults: the prognostic importance of extent of resection and prior low-grade glioma. J Neurosurg 1989;71:487-93.
7. Alderson LM, Castleberg RL, Harsh GR IV, Louis DN, Henson JW. Human gliomas with wild-type p53 express bcl-2. Cancer Res 1995;55:999-1001.
8. Nakamura M, Konishi N, Tsunoda S, Hiasa Y, Tsuzuki T, Aoki H, et al. Analyses of human gliomas by restriction landmark genomic scanning. J Neurooncol. In press.
9. Sachs L, Lotem J. Control of programmed cell death in normal and leukemic cells: new implications for therapy. Blood 1993;82:15-21.
10. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-62.
11. Borner M, Myers CE, Sartor O, Sei Y, Toko T, Trepel JB, et al. Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3. Cancer Res 1995;55:2122-8.
12. 1 arrest and apoptosis. Proc Natl Acad Sd U S A 1995;92:9019-23.
13. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-67.
14. Bracey TS, Miller JC, Paraskeva C. γ-Radiation-induced apoptosis in human colorectal adenoma and carcinoma cell lines can occur in the absence of wild type p53. Oncogene 1995;10:2391-6.
15. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle Checkpoint determinant following irradiation. Proc Natl Acad Sci USA 1992;89:7491-5.
16. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jack T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993;362:847-9.
17. Boise LH, Gonzalez GM, Postema CE, Ding L, Lindsten T, Turka LA, et al. Bcl-x, a Bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74:597-608.
18. Clarke AR, Pardie CA, Harrison DJ, Morris RG, Bird CC, Hooper MI, et al. Thymocyte apoptosis induced by p53 dependent and independent pathways. Nature 1993;362:849-52.
19. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994;124:1-6.
20. Symonds H, Krall L, Remington L, Saenz-Robles M, Lowe S, Jacks T, et al p53 dependent apoptosis suppresses tumor growth and progression in vivo. Cell 1994;78:703-11.
21. Haupt Y, Rowan S, Oren M, Qin XQ, Livingston DM, Ewen M, et al. The transcription factor E2F-1 is a downstream target of RB action. Mol Cell Biol 1995;15:742-55.
22. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81:323-30.
23. Berry DE, Lu Y, Schmidt B, Fallon PG, O'Connel C, Hu SX. Retinoblastoma protein inhibits IFN-γ induced apoptosis. Oncogene 1996;12:1809-19.
24. Haas-Kogan DA, Kogan SC, Levi D, Dazin P, TOAng A, Fung YK, et al. Inhibition of apoptosis by the retinoblastoma gene product. EMBO J 1995;14:461-72.
25. Hansen R, Reddel R, Braithwaite A. The transforming oncoproteins determine the mechanisms by which p53 suppresses cell transformation: pRb-mediated growth arrest or apoptosis. Oncogene 1995;11:2535-45.
26. Haupt Y, Rowan S, Oren M. p53-mediated apoptosis in Hela cells can be overcome by excess pRB. Oncogene 1995; 10:1563-71.
27. Morgenbesser SD, Williams BO, Jacks T, DePinho RA. p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature 1994;371:72-4.
28. Qin XQ, Livingston DM, Kaelin WG Jr., Adams PD. Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediatcd apoptosis. Proc Natl Acad Sci U S A 1994;91:10918-22.
29. Shan B, Durfee T, Lee WH. Disruption of RB/E2F-1 interaction by single point mutations in E2F-1 enhances S-phase entry and apoptosis. Proc Natl Acad Sci U S A 1996;93:679-84.
30. Shan B, Lee WH. Deregulated expression of E2F-1 induces S-phase entry and leads to apoptosis. Mol Cell Biol 1994; 14:8166-73.
31. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:493-501.
32. Isacson C, Kessis TD, Hedrick L, Cho KR. Both cell proliferation and apoptosis increase with lesion grade in cervical neoplasia but do not correlate with human papillomavirus type. Cancer Res 1996;56:669-74.
33. Kordek R, Hironishi M, Liberski PP, Yanagihara R, Gajdusek DC. Apoptosis in glial tumors as determined by in situ non-radioactive labeling of DNA breaks. Acta Neuropathol 1996;91:112-6.
34. Kleihues P, Burger PC, Scheithauer BW. Histological typing of tumours of the central nervous system. Berlin: Springer-Verlag, 1993.
35. Cattoretti G, Becker MHG, Key G, Duchrow M, Schlÿter C, Galle C, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB1 and MIB3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992;168:357-63.
36. Domagala W, Markiewski M, Harezga B, Dukowicz A, Osborn M. Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: its relationship with vimentin and p53 protein. Clin Cancer Res 1996;2:147-54.
37. INK4a expression in resected non-small cell lung tumors. Cancer Res 1996; 56:3415-20.
38. Xu H-J, Quinlan DC, Davidson AG, Hu SX, Summers CL, Li J, et al. Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung cancer. J Natl Cancer Inst 1994;86:695-9.
39. Xu H-J, Cagle PT, Hu S-X, Li J, Benedict WF. Altered retinoblastoma and p53 protein status in non-small cell carcinoma of the lung: potential synergistic effects on prognosis. Clin Cancer Res 1996;2:1169-76.
40. Zhang X, Xu H-J, Murakami Y, Sachse R, Yashima K, Hirohashi S, et al. Deletions of chromosome 13q, mutations in retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma. Cancer Res 1994;54:4177-82.
41. Bodner SM, Minna JD, Jensen SM, DOAmico D, Carbone D, Mitsudomi T, et al. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutations. Oncogene 1992;7.743-9.
42. Kupryjanczyk J, Thor AD, Beauchamp R, Merritt V, Edgerton SM, Bell DA, et al p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci U S A 1993;90:4961-5.
43. Kyritsis AP, Xu R, Bondy ML, Levin VA, Bruner JM. Correlation of p53 immunoreactivity and sequencing in patients with glioma. Mol Carcinog 1996;15:1-4.
44. Nishio M, Koshikawa T, Kuroishi T, Suyama M, Uchida K, Takagi Y, et al. Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers. J Clin Oncol 1996;14:497-502.
45. Tsuzuki T, Tsunoda S, Sakaki T, Konishi N, Hiasa Y, Nakamura M. Alterations of RB, p53, p16 (CDKN2), and p15 genes in human astrocytomas. Cancer 1996;78:287-93.
46. INK4 or retinoblastoma protein (pRB), or amplification-associated over expression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res 1995;55:4833-6.
47. Schmidt EE, Ichimura K, Reifenberger G, Collins VP. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 1995;54:6321-4.
48. Sherr CJ. Mammalian G1 cyclins. Cell 1993;73:1059-65.